EBS
Emergent BioSolutions Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$472M
5Y Perf.-89.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
EBS vs BRKR
Revenue, margins, valuation, and 5-year total return — side by side.
BRKR
Bruker Corporation
Medical - Devices
Market Cap$6.66B
5Y Perf.+1.0%
EBS vs BRKR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EBS | BRKR |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Devices |
| Market Cap | $472M | $6.66B |
| Revenue (TTM) | $743M | $3.46B |
| Net Income (TTM) | $53M | $-12M |
| Gross Margin | 47.1% | 45.3% |
| Operating Margin | 14.7% | 4.9% |
| Forward P/E | 17.6x | 20.7x |
| Total Debt | $572M | $2.04B |
| Cash & Equiv. | $205M | $299M |
EBS vs BRKR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EBS
BRKR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Emergent BioSolutio… (EBS) | 100 | 10.9 | -89.1% |
| Bruker Corporation (BRKR) | 100 | 101.0 | +1.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EBS vs BRKR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: EBS leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Bruker Corporation is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
EBS
Emergent BioSolutions Inc.
The Income Pick
EBS carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 1 yrs, beta 1.83
- Lower P/E (17.6x vs 20.7x)
- 7.1% margin vs BRKR's -0.3%
Best for: income & stability
BRKR
Bruker Corporation
The Growth Play
BRKR is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 2.1%, EPS growth -119.7%, 3Y rev CAGR 10.7%
- 67.1% 10Y total return vs EBS's -76.6%
- Lower volatility, beta 1.59, Low D/E 81.4%, current ratio 1.73x
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BRKR | 2.1% revenue growth vs EBS's -28.8% |
| Value | EBS | Lower P/E (17.6x vs 20.7x) |
| Quality / Margins | EBS | 7.1% margin vs BRKR's -0.3% |
| Stability / Safety | BRKR | Beta 1.59 vs EBS's 1.83, lower leverage |
| Dividends | BRKR | 0.3% yield; the other pay no meaningful dividend |
| Momentum (1Y) | EBS | +92.7% vs BRKR's +7.8% |
| Efficiency (ROA) | EBS | 3.7% ROA vs BRKR's -0.2%, ROIC 8.5% vs 4.4% |
EBS vs BRKR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
EBS vs BRKR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEBSLAGGINGBRKR
BRKRBruker Corporation
1leads
EBSEmergent BioSolutions…
4leads
6 Total Categories
CATEGORYLEADERvs BRKRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
EBS5/6
Valuation MetricsMultiples, price ratios, and targets
EBS5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
EBS8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
BRKR2/2
Analyst OutlookRatings, price targets, and dividends
EBS1/1
Income & Cash Flow (Last 12 Months)
EBS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BRKR is the larger business by revenue, generating $3.5B annually — 4.7x EBS's $743M. EBS is the more profitable business, keeping 7.1% of every revenue dollar as net income compared to BRKR's -0.3%. On growth, BRKR holds the edge at +2.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | EBSEmergent BioSolut… | BRKRBruker Corporation |
|---|---|---|
| RevenueTrailing 12 months | $743M | $3.5B |
| EBITDAEarnings before interest/tax | $207M | $397M |
| Net IncomeAfter-tax profit | $53M | -$12M |
| Free Cash FlowCash after capex | $157M | $51M |
| Gross MarginGross profit ÷ Revenue | +47.1% | +45.3% |
| Operating MarginEBIT ÷ Revenue | +14.7% | +4.9% |
| Net MarginNet income ÷ Revenue | +7.1% | -0.3% |
| FCF MarginFCF ÷ Revenue | +21.1% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -23.6% | +2.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -76.3% | -79.2% |
EBS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
EBS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, EBS's 4.0x EV/EBITDA is more attractive than BRKR's 18.4x.
| Metric | EBSEmergent BioSolut… | BRKRBruker Corporation |
|---|---|---|
| Market CapShares × price | $472M | $6.7B |
| Enterprise ValueMkt cap + debt − cash | $838M | $8.4B |
| Trailing P/EPrice ÷ TTM EPS | 9.82x | -291.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.57x | 20.68x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 4.02x | 18.41x |
| Price / SalesMarket cap ÷ Revenue | 0.64x | 1.94x |
| Price / BookPrice ÷ Book value/share | 0.99x | 2.64x |
| Price / FCFMarket cap ÷ FCF | 3.01x | 153.73x |
EBS leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
EBS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
EBS delivers a 9.6% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-0 for BRKR. BRKR carries lower financial leverage with a 0.81x debt-to-equity ratio, signaling a more conservative balance sheet compared to EBS's 1.09x. On the Piotroski fundamental quality scale (0–9), EBS scores 7/9 vs BRKR's 4/9, reflecting strong financial health.
| Metric | EBSEmergent BioSolut… | BRKRBruker Corporation |
|---|---|---|
| ROE (TTM)Return on equity | +9.6% | -0.5% |
| ROA (TTM)Return on assets | +3.7% | -0.2% |
| ROICReturn on invested capital | +8.5% | +4.4% |
| ROCEReturn on capital employed | +9.1% | +5.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 |
| Debt / EquityFinancial leverage | 1.09x | 0.81x |
| Net DebtTotal debt minus cash | $367M | $1.7B |
| Cash & Equiv.Liquid assets | $205M | $299M |
| Total DebtShort + long-term debt | $572M | $2.0B |
| Interest CoverageEBIT ÷ Interest expense | 1.84x | 1.14x |
EBS leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — EBS and BRKR each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BRKR five years ago would be worth $6,447 today (with dividends reinvested), compared to $1,482 for EBS. Over the past 12 months, EBS leads with a +92.7% total return vs BRKR's +7.8%. The 3-year compound annual growth rate (CAGR) favors EBS at 0.1% vs BRKR's -16.9% — a key indicator of consistent wealth creation.
| Metric | EBSEmergent BioSolut… | BRKRBruker Corporation |
|---|---|---|
| YTD ReturnYear-to-date | -27.0% | -9.0% |
| 1-Year ReturnPast 12 months | +92.7% | +7.8% |
| 3-Year ReturnCumulative with dividends | +0.2% | -42.5% |
| 5-Year ReturnCumulative with dividends | -85.2% | -35.5% |
| 10-Year ReturnCumulative with dividends | -76.6% | +67.1% |
| CAGR (3Y)Annualised 3-year return | +0.1% | -16.9% |
Evenly matched — EBS and BRKR each lead in 3 of 6 comparable metrics.
Risk & Volatility
BRKR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BRKR is the less volatile stock with a 1.59 beta — it tends to amplify market swings less than EBS's 1.83 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BRKR currently trades 77.8% from its 52-week high vs EBS's 65.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EBSEmergent BioSolut… | BRKRBruker Corporation |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.83x | 1.59x |
| 52-Week HighHighest price in past year | $14.06 | $56.22 |
| 52-Week LowLowest price in past year | $4.72 | $28.53 |
| % of 52W HighCurrent price vs 52-week peak | +65.0% | +77.8% |
| RSI (14)Momentum oscillator 0–100 | 61.4 | 64.8 |
| Avg Volume (50D)Average daily shares traded | 873K | 1.9M |
BRKR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
EBS leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates EBS as "Buy" and BRKR as "Buy". Consensus price targets imply 31.4% upside for EBS (target: $12) vs 19.2% for BRKR (target: $52). BRKR is the only dividend payer here at 0.34% yield — a key consideration for income-focused portfolios.
| Metric | EBSEmergent BioSolut… | BRKRBruker Corporation |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $12.00 | $52.13 |
| # AnalystsCovering analysts | 15 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | +0.3% |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | $0.15 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.3% | +0.2% |
EBS leads this category, winning 1 of 1 comparable metric.
Key Takeaway
EBS leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). BRKR leads in 1 (Risk & Volatility). 1 tied.
Best OverallEmergent BioSolutions Inc. (EBS)Leads 4 of 6 categories
Loading custom metrics...
EBS vs BRKR: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is EBS or BRKR a better buy right now?
For growth investors, Bruker Corporation (BRKR) is the stronger pick with 2.
1% revenue growth year-over-year, versus -28. 8% for Emergent BioSolutions Inc. (EBS). Emergent BioSolutions Inc. (EBS) offers the better valuation at 9. 8x trailing P/E (17. 6x forward), making it the more compelling value choice. Analysts rate Emergent BioSolutions Inc. (EBS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EBS or BRKR?
On forward P/E, Emergent BioSolutions Inc.
is actually cheaper at 17. 6x.
03Which is the better long-term investment — EBS or BRKR?
Over the past 5 years, Bruker Corporation (BRKR) delivered a total return of -35.
5%, compared to -85. 2% for Emergent BioSolutions Inc. (EBS). Over 10 years, the gap is even starker: BRKR returned +67. 1% versus EBS's -76. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EBS or BRKR?
By beta (market sensitivity over 5 years), Bruker Corporation (BRKR) is the lower-risk stock at 1.
59β versus Emergent BioSolutions Inc. 's 1. 83β — meaning EBS is approximately 16% more volatile than BRKR relative to the S&P 500. On balance sheet safety, Bruker Corporation (BRKR) carries a lower debt/equity ratio of 81% versus 109% for Emergent BioSolutions Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — EBS or BRKR?
By revenue growth (latest reported year), Bruker Corporation (BRKR) is pulling ahead at 2.
1% versus -28. 8% for Emergent BioSolutions Inc. (EBS). On earnings-per-share growth, the picture is similar: Emergent BioSolutions Inc. grew EPS 125. 8% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, BRKR leads at 10. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EBS or BRKR?
Emergent BioSolutions Inc.
(EBS) is the more profitable company, earning 7. 1% net margin versus -0. 3% for Bruker Corporation — meaning it keeps 7. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EBS leads at 14. 8% versus 6. 9% for BRKR. At the gross margin level — before operating expenses — EBS leads at 47. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EBS or BRKR more undervalued right now?
On forward earnings alone, Emergent BioSolutions Inc.
(EBS) trades at 17. 6x forward P/E versus 20. 7x for Bruker Corporation — 3. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EBS: 31. 4% to $12. 00.
08Which pays a better dividend — EBS or BRKR?
In this comparison, BRKR (0.
3% yield) pays a dividend. EBS does not pay a meaningful dividend and should not be held primarily for income.
09Is EBS or BRKR better for a retirement portfolio?
For long-horizon retirement investors, Bruker Corporation (BRKR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Emergent BioSolutions Inc. (EBS) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BRKR: +67. 1%, EBS: -76. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EBS and BRKR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EBS is a small-cap deep-value stock; BRKR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(EBS: -23.6% · BRKR: 2.7%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.